INJECTABLE HYDROGEL COMPOSITION HAVING ENDOGENOUS PROGENITOR OR STEM CELL RECRUITMENT AND INDUCTION OF VASCULAR DIFFERENTIATION OF RECRUITED CELLS
20220409775 · 2022-12-29
Assignee
Inventors
Cpc classification
C08L5/08
CHEMISTRY; METALLURGY
C08L5/08
CHEMISTRY; METALLURGY
A61L2300/25
HUMAN NECESSITIES
A61L27/227
HUMAN NECESSITIES
A61L27/3895
HUMAN NECESSITIES
A61L27/54
HUMAN NECESSITIES
International classification
Abstract
The present invention relates to an injectable hydrogel composition having the recruitment of endogenous progenitors or stem cells and the induction of vascular differentiation of recruited cells, and more specifically to an injectable hydrogel composition having the recruitment of endogenous progenitors or stem cells and the induction of vascular differentiation of recruited cells, which consists of: a first solution including anionic hyaluronic acid into which a vascular differentiation inducing factor is introduced; and a second solution including a cationic material, wherein a stem cell recruitment factor is further included in the first solution and/or the second solution, and wherein a hydrogel is formed by electrostatic interaction.
In the hydrogel composition of the present invention, it was confirmed that the stem cell recruitment factor was released from the injected hydrogel, and endogenous progenitor cells/stem cells were recruited in the hydrogel, and the induction of angiogenesis was promoted by differentiating into vascular cells by the vascular differentiation inducing factor chemically introduced into hyaluronic acid. In particular, it was confirmed that when the vascular differentiation inducing factor was chemically introduced into hyaluronic acid, a high angiogenesis-inducing effect was observed. Therefore, the hydrogel composition of the present invention has excellent recruitment of endogenous progenitor cells/stem cells and induction of vascular differentiation, and thus, it can be effectively applied to various tissue regenerations and wound treatments in addition to the formation of blood vessels.
Claims
1. An injectable hydrogel composition having the recruitment of endogenous progenitors or stem cells and the induction of vascular differentiation of recruited cells, consisting of: a first solution comprising anionic hyaluronic acid into which a vascular differentiation inducing factor is introduced; and a second solution comprising a cationic material, wherein a stem cell recruitment factor is further comprised in any one or more of the first solution and the second solution, and wherein when the first solution and the second solution are mixed, a hydrogel is formed by electrostatic interaction.
2. The injectable hydrogel composition of claim 1, wherein the vascular differentiation inducing factor is a vascular endothelial cell growth factor mimic peptide.
3. The injectable hydrogel composition of claim 2, wherein the vascular endothelial cell growth factor mimic peptide comprises the amino acid sequence represented by SEQ ID NO: 1.
4. The injectable hydrogel composition of claim 1, wherein the anionic hyaluronic acid into which the vascular differentiation inducing factor is introduced is prepared by reacting the vascular differentiation inducing factor and anionic hyaluronic acid in which a carboxylic acid functional group is activated.
5. The injectable hydrogel composition of claim 1, wherein the cationic material is at least one selected from the group consisting of chitosan, cationic dextran, polyethyleneimine, polylysine and polyhistidine.
6. The injectable hydrogel composition of claim 1, wherein the stem cell recruitment factor is at least one selected from the group consisting of substance P, WKYMVM, SDF1α, G-SCF and MCP-1.
7. The injectable hydrogel composition of claim 1, wherein the ratio of the anionic hyaluronic acid into which the vascular differentiation inducing factor of the first solution is introduced and the cationic material of the second solution is 3:1 to 1:3.
8. The injectable hydrogel composition of claim 1, wherein the storage modulus of the hydrogel formed by mixing the first solution and the second solution is 10 to 100 Pa.
9. An injection for tissue regeneration, comprising the injectable hydrogel composition according to claim 1.
10. An injection for fillers, comprising the injectable hydrogel composition according to claim 1.
Description
DESCRIPTION OF DRAWINGS
[0046]
[0047]
[0048]
[0049]
[0050]
[0051]
[0052]
[0053]
[0054]
[0055]
[0056]
[0057]
[0058]
[0059]
[0060]
[0061]
MODES OF THE INVENTION
EXAMPLE 1
[0062] Preparation of hyaluronic acid in which vascular endothelial growth factor mimic peptide is introduced
[0063] In the present invention, in order to prepare an injectable hydrogel composition having the recruitment of endogenous progenitor cells or stem cells and the induction of vascular differentiation of the recruited cells, first, hyaluronic acid into which a vascular endothelial growth factor mimic peptide was introduced was prepared.
[0064] Specifically, an HA solution was prepared by dissolving hyaluronic acid (HA) in distilled water at 10 mg/mL, and then 0.3 mg of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM, Sigma, USA) was added to 10 mL of the HA solution and stirred for 1 hour to activate the carboxylic acid functional group of hyaluronic acid.
[0065] 10 mL of the HA solution in which the carboxylic acid functional group was activated was added dropwise to a VP solution prepared by dissolving 1.9 mg of the vascular endothelial growth factor mimic peptide (VP, SEQ ID NO: 1: KLTWQELYQLKYKGI) in 1 mL of distilled water, and it was reacted by stirring for 24 hours. The reaction solution was dialyzed for 72 hours and freeze-dried at −80° C. to prepare HA-VP into which VP was introduced.
[0066] As shown in Tables 1 and 2 below, the VP introduced into the HA was confirmed through TNBSA analysis (Table 1) and elemental analysis (Table 2).
TABLE-US-00001 TABLE 1 VP (μg/ VP (μg/ Introduction Sample mg).sub.cald mg).sub.meas ratio (%) HA-VP 19.1 16.0 84
TABLE-US-00002 TABLE 2 C/N Intro- C H N mole DS DS duction Sample (%) (%) (%) ratio (%), .sub.cald (%), .sub.EA ratio (%) HA 34.5 5.7 2.8 14.45 — — — HA-VP 38.3 5.7 3.2 13.86 0.40 0.34 85
EXAMPLE 2
Measurement of Zeta Potential and Rheological Properties According to the Ratio of Chitosan and HA-VP
[0067] In the present invention, in order to confirm whether the HA-VP and chitosan prepared in Example 1 above formed a hydrogel through electrostatic interaction, the Zeta potential and rheological properties according to the ratio of chitosan and HA-VP were measured.
[0068] First, a CH solution was prepared by dissolving chitosan (CH, sigma, USA) in a 0.1 M aqueous acetic acid solution at a concentration of 20 mg/mL, and HA-VP was dissolved in distilled water at 20 mg/mL to prepare an HA-VP solution.
[0069] The CH solution and the HA-VP solution were mixed in proportions and the zeta potential of the hydrogel formed through electrostatic bonding was measured with ELS-Z (Otsuka Electronics, Japan), and the rheological properties were measured with a modular compact rheometer (MCR 102, Anton Paar, Austria). The measurement conditions for rheological properties were that the parallel plate had a diameter of 25 mm, the distance from the bottom surface was 0.3 mm, and the strain was 2% at 25° C. and 1 Hz.
[0070] As a result, as shown in
EXAMPLE 3
Preparation of Hydrogel Through Electrostatic Interaction
3-1: Preparation of Hydrogel According to the Type of Cationic Material and Anionic Material
[0071] In the present invention, hydrogels were prepared by electrostatic interaction by respectively mixing the cationic polymer chitosan (CH), cationic dextran (CD), polyethyleneimine (PEI), polylysine (PL) or polyhistidine (PH) and anionic HA or hyaluronic acid (HA-VP) introduced with a vascular endothelial growth factor mimic peptide.
[0072] First, a CH solution was prepared by dissolving chitosan (CH, sigma, USA) in a 0.1 M aqueous acetic acid solution at a concentration of 20 mg/mL, and CD, PEI, PL, PH, HA and HA-VP were each dissolved in distilled water at 20 mg/mL to prepare a CD solution, a PEI solution, a PL solution, a PH solution, an HA solution and an HA-VP solution.
[0073] Then, hydrogels were prepared by mixing the CH solution, CD solution, PEI solution, PL solution or PH solution and HA solution, or the CH solution, CD solution, PEI solution, PL solution or PH solution and HA-VP solution in the same volume.
[0074] As a result, as shown in
3-2: Preparation of Hydrogel According to Stem Cell Recruitment Factor
[0075] A CHHA hydrogel or CHHA-VP hydrogel was prepared by mixing the CH solution and the HA solution prepared in Example 3-1 or the CH solution and the HA-VP solution in the same volume. In addition, one of SP, WKYMVM, SDF1a, G-SCF and MCP-1 (Genscript, USA) was dissolved in each of the CH, HA and HA-VP solutions having the same concentration at a concentration of 1 μg/mL, respectively, to prepare solutions, and it was carried out in the same way as forming the hydrogels previously.
TABLE-US-00003 TABLE 3 Stem cell recruitment factor Classification Protein Peptide Peptide sequence Stem cell Substance RPKPQQFFGLM recruitment P (SP) (SEQ ID NO: 2) factor WKYMVM WKYMVM (SEQ ID NO: 3) SDF1 MCP-1 G-SCF
[0076] As shown in
EXAMPLE 4
Evaluation of Rheological Properties of Hydrogel
[0077] In order to evaluate the rheological properties of the CHHA and CHHA-VP hydrogels prepared in Example 3 above, the modulus and viscosity were measured using a modular compact rheometer (MCR 102, Anton Paar, Austria). In this case, the used parallel plate had a diameter of 25 mm, an interval from the bottom surface of 0.3 mm, and a strain of 2% at 25° C. and 1 Hz.
[0078] As a result, as shown in
EXAMPLE 5
Confirmation of Release Behavior of Stem Cell Recruitment Factor and VP In Vitro
[0079] In the present invention, it was attempted to confirm the release degree of the stem cell recruitment factor and VP in the hydrogels prepared by electrostatic interaction.
[0080] First, an HA+VP solution was prepared by simply mixing VP with the HA solution prepared in Example 3 at a concentration of 320 μg/mL, and SP, which is a stem cell recruitment factor, was mixed with each of the HA solution and HA-VP solution at a concentration of 2 μg/mL to prepare an HA+SP solution and HA−VP+SP solution, respectively.
[0081] Next, 100 μL of the CH solution and 100 μL of the HA+VP solution were mixed in a vial to prepare 200 μL of a CHHA+VP hydrogel, and 100 μL of the CH solution and 100 μL of the HA-VP solution were mixed in a vial to prepare 200 μL of a CHHA-VP hydrogel.
[0082] In addition, 100 μL of the CH solution and 100 μL of HA+SP solution were mixed in a vial to prepare 200 μL of a CHHA+SP hydrogel, and 100 μL of the CH solution and 100 μL of the HA-VP+SP solution were mixed in a vial to prepare 200 μL of a CHHA-VP+SP hydrogel.
[0083] 3 mL of a physiological saline was placed in each vial and stored in an incubator at 100 rpm and 37° C., and after taking 1 mL of the physiological saline from the vial at a predetermined time, 1 mL of a new physiological saline was added to the vial, and it was carried it out for 28 days to conduct a release experiment.
[0084] As a result, as shown in
[0085] In addition, as shown in
EXAMPLE 6
Toxicity Evaluation of Hydrogel
[0086] The presence or absence of toxicity of the hydrogels prepared in the present invention was evaluated.
[0087] First, human mesenchymal stem cells (hMSCs) were mixed at a concentration of 1×10.sup.6 cells/mL in each of the CH, HA, HA-VP solutions prepared in Example 3 above and the HA+VP solution prepared in Example 5 above.
[0088] Cytotoxicity evaluation test was performed for the prepared solutions, and in order to form hydrogels, (1) 200 μL of the CH solution and 200 μL of the HA solution were mixed to form 400 μL of a CHHA hydrogel, (2) 200 μL of the CH solution and 200 μL of the HA+VP solution were mixed to form 400 μL of a CHHA+VP hydrogel, and (3) 200 μL of the CH solution and 200 μL of the HA-VP solution were mixed to form 400 μL of a CHHA-VP hydrogel in 24-well plates. As a control group for comparison, 4×10.sup.5 hMSC cells were added to a 24-well plate. The medium was added by 1 mL and was replaced every 3 days, and cytotoxicity was measured by MTT analysis on days 1, 4 and 7.
[0089] As a result, as shown in
EXAMPLE 7
Confirmation of SP's Ability to Recruit Stem Cells
[0090] In the present invention, the ability of the SP to recruit stem cells was confirmed.
[0091] First, human-derived mesenchymal stem cells (hMSCs) were labeled with PKH 26 dye (Sigma, USA) and then dispensed in the upper chamber (8.0 μm pore size) of a 24-well trans well plate (SPL, Korea) to be 5×10.sup.4 cells. After culturing in the upper chamber for 48 hours using serum-free DMEM (Dubelco's modified eagle medium, Gibco, USA) medium, DMEM containing 1 μg/mL SP and 1% FBS (fetal bovine serum, Gibco, USA) was added to the bottom well, and the medium was replaced every 3 days, and the hMSCs that migrated to the bottom well were observed using a fluorescence microscope (Olympus, Japan). As a control group, DMEM (including 1% FBS) without SP was added to the bottom well and observed.
[0092] As a result, as shown in
TABLE-US-00004 TABLE 4 Migration Rate Relative rate of hMSC constant migration (cells/day) (1/day) rate Cont 1.1 × 10.sup.3 −0.47 — SP 1.9 × 10.sup.3 −0.49 1.7
EXAMPLE 8
Confirmation of Angiogenesis Effect by the Hydrogel of the Present Invention In Vitro
8-1: Confirmation of Angiogenesis Through Immunofluorescence Analysis
[0093] In order to confirm the angiogenesis-inducing effect of the injectable hydrogel of the present invention, CHHA, CHHA+VP and CHHA-VP hydrogels including human-derived mesenchymal stem cells were prepared in the same manner as in Example 6, respectively, and the medium was exchanged every 3 days and cultured for 4 weeks.
[0094] At the 1.sup.st 2.sup.nd 3.sup.rd and 4.sup.th weeks of culture, the hydrogel was fixed with formalin, and immunofluorescence analysis was performed to observe the expression of CD31, which is known to be expressed in vascular cells.
[0095] As a result, as shown in
8-2: Confirmation of Angiogenesis Through Gene Expression Change
[0096] After extracting mRNA from the hydrogels of Example 8-1, cDNA was synthesized using the extracted mRNA, and changes in the expressions of the von
[0097] Willebrand factor (vWF) gene and the CD31 gene expressed in vascular cells were confirmed through qRT-PCR (quantitative real-time polymerase chain reaction).
TABLE-US-00005 TABLE 5 Primer sequence Gene Base sequence (5′->3′) SEQ ID NO vWF Forward CGG CTT GCA SEQ ID NO: 4 CCA TTC AGC TA Reverse TGC AGA AGT SEQ ID NO: 5 GAG TAT CAC AGC CAT C CD31 Forward ATT GCA GTG SEQ ID NO: 6 GTT ATC ATC GGA GTG Reverse CTC GTT GTT SEQ ID NO: 7 GGA GTT CAG AAG TGG GAPDH Forward GAA GGT GAA SEQ ID NO: 8 GGT CGG AGT C Reverse GAA GAT GGT SEQ ID NO: 9 GAT GGG ATT TC
[0098] As a result, as shown in
EXAMPLE 9
[0099] Confirmation of recruitment of stem cells by hydrogel in vivo It was confirmed whether the actual stem cells were recruited in vivo by the hydrogel of the present invention.
[0100] First, for fluorescence imaging, 1 μg/mL of SP, which is a stem cell recruitment factor, was added to each of an FITC-labeled chitosan (CH) solution and a hyaluronic acid (HA) solution, and a total of 200 μL of the hydrogel by 100 μL, each was injected subcutaneously in nude mice through a dual syringe.
[0101] Afterwards, 1×10.sup.6 hMSCs labeled with IR-783 were injected into the tail vein of nude mice, and cell migration was observed through fluorescence imaging. The results are shown in
[0102] As a result, as shown in
EXAMPLE 10
Confirmation of Induction of Angiogenesis by Hydrogel In Vivo
10-1: Preparation and Injection of Hydrogel
[0103] It was confirmed whether actual angiogenesis was induced in vivo by the hydrogel of the present invention.
[0104] First, 1 μg/mL of SP, which is a stem cell recruitment factor, was added to the CH, HA, HA+VP, and HA-VP solutions, respectively, and then, a total of 200 p.1_, of the hydrogel by 100 μL each was injected subcutaneously in nude mice through a dual syringe in the combination of CH and HA, CH and HA+VP, and CH and HA-VP. For comparison, the CH, HA, HA+VP and HA-VP solutions without the recruitment factor were injected in the same way. Afterwards, 1×10.sup.6 hMSCs labeled with BrdU were injected into the tail vein of nude mice. The hydrogel was extracted at the 1st 2nd 3rd and 4th weeks, and it was observed whether angiogenesis occurred.
[0105] As a result, as shown in
10-2: Confirmation of Angiogenesis Through Immunofluorescence Analysis
[0106] Immunofluorescence analysis was performed on BrdU and CD31 to confirm the degrees of hMSCs recruited in the hydrogels extracted in Example 10-1 and angiogenesis. The observation results are shown in
[0107] As a result, as shown in
[0108] In the case of CD31 stained green, it was confirmed that the number of cells expressing CD31 was increased when VP was chemically introduced, compared to when VP was physically mixed.
[0109] Further, in the case of cells stained with BrdU and CD31 at the same time, it was confirmed that it was increased more in the hydrogel in which VP was chemically introduced, and through this, it was confirmed that the differentiation into vascular cells and the promotion of angiogenesis were more effectively induced in the presence of the recruitment factor by VP which was chemically introduced and recruited hMSCs inside the hydrogel than VP which was simply mixed.
10-3: Confirmation of Angiogenesis Through Gene Expression Change
[0110] The mRNA was extracted from the hydrogels extracted in Example 10-1, and qRT-PCR was performed in the same manner as in Example 8-2.
[0111] As a result, as shown in
Industrial Applicability
[0112] In the hydrogel composition having the recruitment of endogenous progenitors or stem cells and the induction of vascular differentiation of recruited cells according to the present invention, it was confirmed that the stem cell recruitment factor was released from the injected hydrogel, and endogenous progenitor cells/stem cells were recruited in the hydrogel, and the induction of angiogenesis was promoted by differentiating into vascular cells by the vascular differentiation inducing factor chemically introduced into hyaluronic acid. In particular, it was confirmed that when the vascular differentiation inducing factor was chemically introduced into hyaluronic acid, a high angiogenesis-inducing effect was observed. Therefore, the hydrogel composition of the present invention has excellent recruitment of endogenous progenitor cells/stem cells and induction of vascular differentiation, and thus, since it can be effectively applied to various tissue regenerations and wound treatments in addition to the formation of blood vessels, it has high industrial applicability.
Sequence List Free Text
[0113] SEQ ID NO: 1 shows the amino acid sequence of the vascular endothelial growth factor mimic peptide, which is a vascular differentiation inducing factor.
[0114] SEQ ID NO: 2 shows the amino acid sequence of the substance P (SP) peptide, which is a stem cell recruitment factor.
[0115] SEQ ID NO: 3 shows the amino acid sequence of the WKYMVM peptide, which is a stem cell recruitment factor.
[0116] SEQ ID NO: 4 shows the nucleotide sequence of the forward primer of vWF.
[0117] SEQ ID NO: 5 shows the nucleotide sequence of the reverse primer of vWF.
[0118] SEQ ID NO: 6 shows the nucleotide sequence of the forward primer of CD31.
[0119] SEQ ID NO: 7 shows the nucleotide sequence of the reverse primer of CD31.
[0120] SEQ ID NO: 8 shows the nucleotide sequence of the forward primer of GAPDH.
[0121] SEQ ID NO: 9 shows the nucleotide sequence of the reverse primer of GAPDH.